The gene for human granulocyte/macrophage colony-stimulating factor (GM-CSF) is expressed in a tissue-speciflic as well as an activation-dependent manner. The interaction of nuclear proteins with the promoter region of the GM-CSF gene that is likely to be responsible for this pattern of GM-CSF expression was investigated. We show that nuclear proteins interact with DNA fragments from the GM-CSF promoter in a cell-specific manner. A region spanning two cytokine-specific sequences, cytokine 1 (CK-1, 5' GAGATTC-CAC 3') and cytokine 2 (CK-2, 5' TCAGGTA 3') bound two nuclear proteins [nuclear factor (NF)-GMa and NF-GMb] 
from GM-CSF-expressing cells in gel retardation assays. NFGMb was inducible with phorbol 12-myristate 13-acetate and accompanied induction of GM-CSF message. NF-GMb was absent in cell lines not producing GM-CSF, some of which had other distinct binding proteins. NF-GMa and NF-GMb eluted from a heparin-Sepharose column at 0.3 and 0.6 M KCI, respectively. We hypothesize that the sequences CK-1 and CK-2 bind specific proteins and regulate GM-CSF transcription.
Human granulocyte/macrophage colony-stimulating factor (GM-CSF) is a 22-kDa glycoprotein that stimulates the formation of granulocyte, macrophage, granulocyte/macrophage, and eosinophil colonies from normal bone marrow progenitor cells in vitro (1) . GM-CSF has direct action also on the function of mature peripheral blood granulocytes (2, 3) . The gene encoding human GM-CSF is 2.5-3 kilobases long (4, 5) and maps to the long arm of chromosome 5 (6) .
Antigen-or mitogen-activated T cells and T-cell lines produce relatively high levels of GM-CSF (7) (8) (9) . Other cytokines such as interleukin 1 and tumor necrosis factor activate the expression of the GM-CSF gene in endothelial cells (10) . Primary human stromal cells can also be induced to produce GM-CSF (11) . It appears that there may be multiple forms of control of GM-CSF production, both at a transcriptional and posttranscriptional level. mRNA stability has been shown to be involved in controlling the induction of mouse GM-CSF in macrophages (12) , and a sequence in the 3'-untranslated region is responsible for the instability of GM-CSF mRNA (13) . It has been reported (14) that a 650-base-pair (bp) fragment from the promoter region of the human GM-CSF gene was involved in T-cell-specific expression of the gene and was only active in phytohemagglutinin/phorbol 12- Computer analysis of the mouse and human GM-CSF genes has shown that the most highly conserved sequences are in the promoter region and in the 3'-noncoding sequence of the mRNA (5) , indicating the potential importance of these regions in the regulation of expression of these genes.
Sequences shared with other cytokines can also be found especially in the promoter region of the genes (5, 15, 16) . Sequences within this promoter region, especially those sequences shared with other cytokine genes, may be the binding sites for nuclear proteins that confer cell specificity or inducibility on the GM-CSF gene.
In this study, we have examined the interaction of the GM-CSF promoter with nuclear proteins from cells that express GM-CSF and from cells where GM-CSF is not produced. We have also used synthetic oligonucleotides to examine the interaction of nuclear proteins with conserved sequences in the GM-CSF promoter. We report cell-specific interactions with promoter regions of the GM-CSF gene.
MATERIALS AND METHODS
DNA Probes. A 650-bp Pst I fragment from the promoter region of the human GM-CSF gene (Fig. la) was cloned into pUC18 and was the source of all fragments used in gel retardation assays (the GM-CSF genomal clone was a gift from J. Gasson, School of Medicine, University of California, Los Angeles). The fragments routinely used were a 445-bp Sac I fragment that was end-labeled with T4 DNA polymerase (Pharmacia, Uppsala, Sweden) (17) and a 199-bp Dde I-Sac I fragment derived from the 3' end of the larger Sac I fragment (Fig. la) that was radiolabeled by end-filling with the Klenow fragment of DNA polymerase 1 (Bresa, Adelaide, Australia) (17) .
Two complementary 41-bp oligonucleotides were synthesized with EcoRI ends (Fig. lb) . Each oligonucleotide was end-labeled with [y-32P]ATP (Bresa) and polynucleotide kinase (Pharmacia). The radiolabeled oligonucleotides were annealed by heating to 100'C for 3 min in 25 mM Tris HCI, pH 7.6/150 mM NaCl and then cooling at room temperature for 15 min. Unlabeled oligonucleotides were also annealed as described above to give a final concentration of 10 ng/,ul and used as specific competitors in the binding reactions.
Cell Lines. U5637 is a human bladder carcinoma cell line that constitutively produces GM-CSF and granulocyte colony-stimulating factor (G-CSF) (18) . HUT78 is a T-lymphoblastoid cell line derived from a patient with Sezary syndrome (19) . SP2/10-Agl4 is a mouse myeloma cell line (20) and LiBr is a human melanoma cell line (21 
Preparation of Nuclear Extracts. Nuclei were prepared as described by Dignam et al. (22) Gel Retardation Assay. For binding reactions, 0.1-1.0 ng of radiolabeled fragment (5-10,000 cpm) was mixed with 1-3 ,ug of nuclear extract in a final volume of 20 ul containing 25 mM Tris-HCl (pH 7.6), 6.25 mM MgCl2, 0.5 mM EDTA, 0.5 mM dithiothreitol, 10% (vol/vol) glycerol, and 80-200 mM KCL. Poly(dIdC) (0.5-3 ug) was used in all reactions as nonspecific competitor. Specific competitors were added to each reaction mixture as described in individual experiments. The reaction mixtures were analyzed on 5% polyacrylamide gels in low-ionic-strength buffer (24) . The gels were preelectrophoresed at 20 V/cm for 2 hr and electrophoresed at the same voltage for 1-2 hr. Following electrophoresis the gels were dried and autoradiographed either overnight or for 1-2 days.
Binding reactions with synthetic oligonucleotides were as described above. The retardation patterns were analyzed on 11% polyacrylamide gels in 0.5 x TBE (1.0 x TBE = 50 mM Tris borate, pH 8.3/1 mM EDTA).
Heparin-Sepharose Column Chromatography. A 1-ml heparin-Sepharose (Pharmacia) column was equilibrated with TM buffer containing 100 mM KCl (TM.1). Six milligrams of crude nuclear extract from PMA-treated U5637 cells was loaded onto the column in the same buffer. Following extensive washing with TM.1, the bound protein was eluted in a stepwise fashion with 3 ml of 0.2 M, 3 ml of 0.3 M, and 3 ml of 0.6 M KCI in TM buffer. The eluates from each salt concentration were collected and dialyzed into TM.1, and the protein concentration was estimated with the Bio-Rad assay. The fractions were tested for binding activity to the synthetic oligonucleotides.
RESULTS

Specific Interaction of Nuclear Proteins with the Promoter
Region of the GM-CSF Gene. A 445-bp Sac I fragment from the GM-CSF promoter region (Fig. la) was radiolabeled and mixed with nuclear extracts prepared from the U5637 bladder carcinoma cell line that had been treated for 6 hr with PMA at 10 ng/ml. Gel retardation assays resulted in a single retarded band ( Fig. 2A) , which was specifically blocked by competition with 100 ng of unlabeled Sac I fragment but not with 500 ng of poly (dI dC) (Fig. 2A, compare lanes 2 and 4) .
To define more precisely the promoter region responsible for the protein-DNA interaction, competition experiments were carried out with a number of smaller fragments spanning the 445-bp region. The binding could be successfully blocked by competition with a 199-bp Dde I-Sac I fragment ( Fig. 2A, lane 6) comprising the region closest to the transcription initiation point (Fig. la) . Fragments further upstream did not compete successfully in the retardation reactions. Fig. 2A (lanes 8 and 9) shows the inability of a 130-bp Pst I-Sac I fragment (positions -603 to -457) to block the binding by competition.
When binding reactions were carried out with radiolabeled 199-bp Dde I-Sac I fragment and nuclear extract from PMA-stimulated U5637 cells, one main retarded complex was observed (Fig. 2B, lane 1) . A fainter complex, migrating closer to the free DNA was seen on longer exposure of the gels to x-ray film (Fig. 2B) . The formation of these complexes could be specifically blocked by competition with 100 ng of unlabeled fragment (Fig. 2B, lane 2) .
Comparison with the 445-bp or 199-bp GM-CSF promo cell-type-specific, we made nuclear prote U5637, HUT78, and SP2 cell lines treated fe at 10 ng/ml. Fig. 3A shows the retarded bar extracts from each cell line following bind Sac I fragment. U5637 and HUT78 extract retarded bands, with the major band corr U5637 band described above (band 3). migrating higher on the gel is also visible (band 2). The SP2 extract, however, show, (band 1) that migrates higher on the gel tha complex from the other cell lines.
We also examined the interaction betwei and the smaller 199-bp fragment. The (Fig. 3B) . The formation cannot be blocked by competition with increasing ell extracts (band concentrations of specific competitor (Fig. 4A) (Fig. lb) KCl were tested in retardation assays (Fig. 4B) . The protein(s) responsible for the NF-GMa complex eluted from the column with 0.3 M KCl and that responsible for NF-GMb eluted with 0.6 M KCl (Fig. 4B , lanes 5 and 6 and lanes 7 and 8, respectively), suggesting the involvement of two distinct proteins in these complexes.
Ceil-Specific Interactions with the Conserved Cytokine Sequence. We have compared the retardation band patterns obtained with extracts prepared from U5637, HUT78, LiBr, and SP2 cell lines. The extracts were prepared from cells treated for 6 hr with PMA at 10 ng/ml. Both of the specific retarded bands NF-GMa and NF-GMb were obtained using the radiolabeled oligonucleotides and extracts from PMAtreated U5637 and HUT78 cells (Fig. 5A, lanes 1 and 2) , although HUT78 cell extracts always yielded a 3-to 4-fold higher concentration of the proteins involved in both these complexes. Extracts from the SP2 cell line did not result in pith various cell line either of the specific complexes but gave a diffuse retarded tngof radiolabeled band migrating above NF-GMa (Fig. SA, lane 3 r than that seen in U5637 cells by a bp fragment, spanning a large area of the promoter, and a lane 4).
199-bp fragment in a region close to the transcription start ilation on the Formation of NF-GMa site. The SP2 cell line, where GM-CSF mRNA is not tein Complexes. To determine if PMA detectable, has proteins that bound to the promoter region of Production of the proteins involved in the GM-CSF gene but formed a complex distinct from that 1c complexes, extracts were prepared found in U5637 or HUT78 cells, where mRNA for GM-CSF iBr cell lines before and after PMA is detectable. Since the human and mouse GM-CSF promot-A patterns obtained with these exers share >80% of the sequences in the first 350 bp, it seems r5637 cells the protein involved in the valid to compare human and mouse cell lines. The presence is induced 5-to 10-fold (Fig. SB, of cell-specific DNA binding proteins has now been shown The induction seen here in the level for a number of gene promoters where it has been hypothe-,istent between experiments. In LiBr sized that these interactions are involved in cell-specific not observed, and no change in the expression (24) (25) (26) (27) (28) . It is possible then that the binding ,een (Fig. 5B, lanes 3 and 4) . One decanucleotide sequence [cytokine 1 (CK-1)], 5' GRGRTTYCAY 3' (where R = A or G and Y = C or T) is found in both human and murine interleukin 2, interleukin 3 (IL-3), GM-CSF, and G-CSF genes (Fig. 6 ). In addition a a-He 'im second sequence [cytokine 2 (CK-2)], 5' TCAGRTA 3', lying on the 3' side of the decanucleotide, is conserved in both bhuman and murine GM-CSF and IL-3 genes (Fig. 6 ). This sequence is not found in human or murine G-CSF or interleukin 2. The CK-1 sequence is also repeated further upstream in the human GM-CSF (14) and murine IL-3 (32) genes but without the extra flanking conserved sequence (CK-2). We designed our 41-bp oligonucleotide probe span- The CK-1 sequence has been postulated to account for the coordinate expression of some of these genes in activated T cells (14, 15) . However, G-CSF is not expressed in activated T cells (13) despite the fact that its promoter contains a copy of CK-1. It seems unlikely, therefore, that this sequence alone is responsible for T-cell expression of GM-CSF or IL-3. However, the extended conserved sequence of CK-1 and CK-2 noted above between GM-CSF and IL-3 genes may be involved in T-cell expression of these genes. It is noteworthy that IL-3 and GM-CSF are often coordinately expressed following Con A stimulation of murine T-cell clones (36) .
Treatment of U5637 cells with PMA results in an increase in GM-CSF mRNA and an increase in the level of the NF-GMb complex but not NF-GMa. The ability to induce the NF-GMb complex in PMA-treated U5637 cells suggests that the protein(s) involved in the NF-GMb complex may be responsible for the inducibility of the GM-CSF gene. However, unstimulated cells also transcribe the GM-CSF gene but have undetectable levels of NF-GMb. Therefore, NFGMb may not be essential for basal level transcription of the gene in this tumor cell line but could be involved in increasing transcriptional efficiency following stimulation. The situation observed here parallels that found with proteins binding to the octamer motif of the immunoglobulin genes (25, 26) . Two proteins, one of which is lymphoid specific, bind to this motif. The lymphoid-specific protein is inducible with lipopolysaccharide (26), as is NF-GMb with PMA in U5637 cells. Extracts from the human melanoma cell line LiBr contain protein(s) that may be equivalent to NF-GMa, but NF-GMb could not be induced by PMA treatment of these cells. Nuclear proteins prepared from the mouse SP2 cell line did not bind specifically to the GM-CSF conserved sequence. It would appear, therefore, that the protein(s) that bind to this GM-CSF sequence are limited in their cellular distribution. The result is consistent with results (14) that show that a GM-CSF-chloramphenicol acetyltransferase fusion gene is expressed in activated T cells but not in a human B-lymphoblastoid cell line. The elucidation of the role of these protein-DNA complexes in GM-CSF transcription awaits analysis of the DNA fragments in vivo by using transfection assays.
